Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): A systematic review and meta-analysis

International Braz J Urol

Volumn 38, Issue 6, 2012, Pages 717-727

  Botrel, Tobias Engel Ayer ^b   Clark, Otávio ^b   Pompeo, Antônio Carlos Lima ^a   Bretas, Francisco Flávio Horta ^a   Sadi, Marcus Vinicius ^a   Ferreira, Ubirajara ^a   Dos Reis, Rodolfo Borges ^a  

^a Comitê Brasileiro de Estudos em Uro Oncologia CoBEU ^*  (Brazil)

^b Evidencias   (Brazil)

Author keywords

Immunotherapy; Meta analysis; Review literature as topic; Sipuleucel T

Indexed keywords

EID: 84874900846     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/1677-553820133806717     Document Type: Review

References (60)

1. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al.: New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011; 60: 279-90.
2. Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther. 2010; 12: 77-85.
3. Chang SS, Kibel AS. The role of systemic cytotoxic therapy for prostate cancer. BJU Int. 2009; 103: 8-17.
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al.: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
5. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al.: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375: 1437-46.
6. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 1756-64.
7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-12.
8. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-20.
9. Bianchini D, Zivi A, Sandhu S, de Bono JS. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann Oncol. 2010; 21(Suppl 7): 43-55.
10. Peskin SR. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival. Manag Care. 2011; 20: 6-11.
11. Gerritsen WR, Sharma P. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol. 2012; 32: 25-35.
12. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002; 117: 471-7.
13. Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer. 1989; 60: 887-92.
14. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al.: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115: 3670-9.
15. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al.: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24: 3089-94.
16. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-22.
17. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994; 309: 1286-91.
18. Clarke M, Oxman AD, (Eds). Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software, 2000.
19. Castro AA, Clark OA, Atallah NA. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999; 117: 138-9.
20. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London: BMJ Books. 2001.
21. Review Manager (RevMan) [Computer program]. Current version: 5.0.24 Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008 (updated on 16 April 2010).
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998 30; 17: 2815-34. Erratum in: Stat Med. 2004; 23: 1817.
23. Higgins JP, Thompson SG, Deeks Jj, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-60.
24. Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010; 30: 229-41.
25. Deeks Jj HJ, Altman DG. Analysing and presenting results, in Higgins JP, Green S (eds): Cochrane Handbook for Systematic Reviews of In- terventions (ed 4.2.6 [updated September 2006]). Chichester, United Kingdom, John Wiley & Sons, Ltd. 2006.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-88.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-34.
28. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997; 126: 712-20.
29. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. BMJ. 1999; 318: 1548-51.
30. Altman DG, Deeks Jj. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002; 2: 3.
31. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151: W65-94.
32. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, et al.: Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol. 2009; 55: 1112-23.
33. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al.: Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009; 27: 5431-8.
34. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-12.
35. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26: 242-5.
36. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999; 18: 465-71.
37. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, et al.: Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011; 186: 877-81.
38. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al.: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet. 2010; 376: 1147-54.
39. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al.: Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011; 17: 4558-67.
40. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, et al.: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999; 53: 260-6.
41. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF. a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009; 18: 1001-11.
42. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010; 20: 241-6.
43. Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol. 2011; 29: 3677-85.
44. Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, et al.: Current vaccination strategies for prostate cancer. Eur Urol. 2012; 61: 290-306.
45. Madan RA, Gulley JL. The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer. 2010; 8: 10-6.
46. May KF, Jr., Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer immunotherapy. Clin Cancer Res. 2011; 17: 5233-8.
47. Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther. 2010; 12: 11-3.
48. McLeod DG, Quinn DI, Whitmore JB, Tabesh M, editors. Sipuleucel-T in African Americans: A subgroup analysis of three phase III sipuleucel-T trials in advanced prostate cancer. J Clin Oncol. 2011; 29: (Suppl; abstr e15148).
49. Fizazi K, Powles T, George DJ, Poehlein CH, editors. A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. J Clin Oncol. 2011; 29: (Suppl; abstr TPS188).
50. Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall S, Xu Y, et al.:, editors. Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer. J Clin Oncol. 2011; 29: (Suppl; abstr 4648).
51. Penson J, Holzbeierlein PA, Schellhammer MW, editors. Study results of active cellular immunotherapy with Sipuleucel-T in androgen independent prostate cancer suggest significant survival benefit with minimal toxicity. http://suonetorg/ pdf/ProgramBooks/2006_SUO_ProgramBookpdf Poster #44.
52. Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2011; 11: 997-1009.
53. Drake CG, Antonarakis ES. Update: immunological strategies for prostate cancer. Curr Urol Rep. 2010; 11: 202-7.
54. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist. 2009; 14: 391-8.
55. Mohebtash M, Madan RA, Gulley JL, Arlen PM. Therapeutic prostate cancer vaccines: a review of the latest developments. Curr Opin Investig Drugs. 2008; 9: 1296-301.
56. Vaishampayan U, Hussain M. Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Rev Anticancer Ther. 2008; 8: 269-81.
57. Harzstark AL, Ryan CJ. Therapies in development for castrate-resistant prostate cancer. Expert Rev Anticancer Ther. 2008; 8: 259-68.
58. Barqawi AB, Crawford ED. The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J. 2007; 13: 313-7.
59. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al.: Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007; 178(4 Pt 1):1515-20.
60. Di Lorenzo G, Autorino R, Figg WD, De Placido S. Hormone-refractory prostate cancer: where are we going Drugs. 2007; 67: 1109-24.